Self/non-self discrimination characterizes immunity and allows responses against pathogens but not self-antigens. Understanding the principles that govern this process is essential for designing autoimmunity treatments. p21 is thought to attenuate autoreactivity by limiting T cell expansion. Here, we provide direct evidence for a p21 role in controlling autoimmune T cell autoreactivity without affecting normal T cell responses. We studied C57BL/6, C57BL/6/lpr and MRL/lpr mice overexpressing p21 in T cells, and showed reduced autoreactivity and lymphadenopathy in C57BL/6/lpr, and reduced mortality in MRL/lpr mice. p21 inhibited effector/memory CD4 1 CD8 1 and CD4 2 CD8 2 lpr T cell accumulation without altering defective lpr apoptosis. This was mediated by a previously non-described p21 function in limiting T cell overactivation and overproduction of IFN-c, a key lupus cytokine. p21 did not affect normal T cell responses, revealing differential p21 requirements for autoreactive and normal T cell activity regulation. The underlying concept of these findings suggests potential treatments for lupus and autoimmune lymphoproliferative syndrome, without compromising normal immunity. p 21 (WAF1) is known mainly for its cell cycle inhibitor properties; it regulates early G1-S transition by inhibiting cyclin-dependent kinases in complex with cyclins A and E or D 1 . It was initially assumed that p21 deletion would lead to extensive tumor development but p21-deficient mice are essentially cancer-free 2,3 . Deficiency in p21 combined with mild autoreactive backgrounds such as 129/Sv 3 C57BL/6 4 or the Gadd45adeficient mice show severe lupus-like autoimmunity glomerulonephritis, which leads to death 5,6 . p21 2/2 mice on the autoimmunity-resistant C57BL/6 (B6) background exhibited mild autoimmune manifestations 7 and it was suggested that p21 acts as a suppressor of autoimmunity. In one report, lack of p21 appeared to reduce disease in autoimmune BXSB male background 8 , and it was considered that this controversy was probably due to the atypical BXSB background 7,9 . The p21 autoimmunity-suppressing activity was reinforced by analysis of Egr-2 deficient autoreactivity-developing mice, which downmodulate p21 expression in T cells 9 .
development of autoimmunity, as they secrete large amounts of IFNc, a cytokine necessary for lupus development in lpr and other spontaneous or induced murine lupus models [19] [20] [21] [22] . C57BL/6/lpr (B6/lpr) mice develop anti-DNA antibodies and mild, non-lethal glomerulonephritis, whereas lpr mice on the autoimmune-prone MRL background (MRL/lpr) show severe autoimmune manifestations that lead to kidney failure and death 18 . Humans with defective Fas/Fas ligand (FasL) signaling develop autoimmune lymphoproliferative syndrome (ALPS) [23] [24] [25] , whose main characteristics are DN T cell accumulation and lymphadenopathy development, propensity to lupus autoimmunity, and increased risk for lymphoma.
To determine a possible therapeutic role for p21 in lupus autoimmunity and to provide direct evidence for an effect of p21 on autoreactive T cells, we analyzed the impact of T cell-directed overexpression of p21 in B6, B6/lpr and MRL/lpr mice. We found that p21 overexpression inhibited B6/lpr DN T cell lymphadenopathy and decreased effector/memory T cell expansion and autoimmune symptoms. Further analysis revealed an unanticipated p21 capacity to decrease the activation of effector/memory B6/lpr T cells and their IFN-c production. p21 is a potent autoimmunity suppressor, since when overexpressed in MRL/lpr mice, efficiently reduced death rates. Exogenous p21 effects were evident in lpr but not in control B6 mice, indicating that autoimmune but not normal T cells require p21 to control activation and IFN-c production. Therefore, therapeutic approaches that target autoimmunity but not normal responses are feasible.
Results
T cell-directed p21 expression inhibits effector/memory T cell accumulation in B6/lpr but not in B6 mice. By two months of age, B6/lpr mice show a predisposition to autoimmunity and begin to accumulate memory and DN T cells in lymphoid organs, with development of autoimmune characteristics and lymphadenopathy 17 . As lack of p21 leads to increased expansion of repeatedly stimulated T cells in vitro without affecting primary T cell responses 7 , we hypothesized that directed transgenic p21 expression in B6/lpr mouse T cells would reduce spontaneous accumulation of effector/ memory T cells and ameliorate lupus characteristics in these mice. We generated B6 and B6/lpr mice that specifically express a human p21 transgene in T cells under the proximal Lck promoter (B6-p21tg and B6/lpr-p21tg), and studied the in vivo characteristics of peripheral T cells. T cell development and differentiation in B6-p21tg mice is normal 26 , as confirmed by similarity of thymic populations in B6 and B6-p21tg and in B6/lpr and B6/lpr-p21tg mice (Fig. S1 ).
Definition of effector and memory T cells is complex, and several subgroups of these cell populations have been described 27 ; here we use the basic definition of effector (CD44 hi /CD62L hi ) and memory (CD44 hi /CD62L lo ) CD4 1 T cells. These two cell groups expand in vivo and accumulate with age in B6 mice, possibly due to exposure to endogenous and environmental antigens. In B6/lpr mice, however, effector/memory CD4 1 T cells accumulate to a much greater extent, as confirmed at two and four months of age ( Fig. 1A, B , left). Enhanced p21 expression in T cells greatly reduced effector and memory CD4 1 T cell accumulation in B6/lpr-p21tg mice at two months, and more so at four months of age as compared to B6/lpr mice (Fig. 1A) . The transgene nonetheless did not affect the percentage of effector and memory T cells in B6-p21tg mice (Fig. 1B) . Even at eight months of age, when effector and memory T cells accumulate in larger proportions, we found no difference between B6 and B6-p21tg mice (Fig. 1B) . CD4 1 T cells from two-month-old B6-p21tg and B6/ lpr-p21tg mice expressed high p21 transgene levels, while endogenous p21 was not detected in these or the equivalent B6 and B6/lpr cells (Fig. 1C) . The human p21 transgene appears as a higher molecular weight band as compared to that of the endogenous p21. The expression of the p21 transgene justified its effect in lowering effector and memory B6/lpr-p21tg T cells. The results indicate that lpr T cells require enhanced p21 expression to control T cell activation and memory levels effectively, whereas exogenous p21 is not needed to regulate B6 T cell activation. p21 overexpression reduces B6/lpr CD4 1 T cell activation and IFN-c production. Enhanced p21 expression severely reduced the lpr effector/memory CD4 1 T cell population, which is large in these mice. We tested whether p21 overexpression affects activation of effector/memory T cells in B6/lpr-p21tg mice, and whether production of inflammatory cytokines such as IFN-c was compromised in this reduced cell population.
CD69 is a major T cell activation marker and is associated with memory T cells 28 . Effector lpr T cells in lymph node showed greatly increased CD69 levels (.4-fold) compared to the equivalent B6 population ( Fig. 2A, left) . This suggested increased cell activation and corroborated the greatly augmented effector T cell population in B6/lpr mice. In B6/lpr-p21tg mice, overexpressed p21 reduced CD69 expression by ,50% in the effector T cell population ( Fig. 2A, top) , whereas exogenous p21 had no effect on the high CD69 levels by memory B6/lpr T cells (Fig. 2B, top) . Enhanced p21 expression thus efficiently reduced not only the elevated percentage of B6/lpr-p21tg effector CD4 1 T cells, but also their activation, as implied by sharply reduced CD69 expression. Overexpressed p21 had no effect on CD69 expression by B6 lymph node effector and memory T cells ( Fig. 2A, B , bottom panels). The data show that exogenous p21 affected mainly CD69-overexpressing effector B6/ lpr T cells, indicating that p21 targets the hyperactivated T cell population.
To determine whether overexpressed p21 interfered with B6/lpr T cell function, we measured inflammatory cytokine production in B6/ lpr and B6/lpr-p21tg effector and memory T cells. We analyzed expression of IFN-c, IL-17 and IL-2, which are associated with the lpr autoimmune phenotype [29] [30] [31] [32] , and the degree of IL-4 secretion as a control. Expression of IFN-c, which modulates anti-DNA antibody production and disease development in several lupus models 33 , was markedly increased by effector and memory CD4 1 T cells in B6/lpr mice compared to B6 controls ( Fig. 3A, B , left panels). Overexpressed p21 led to a sharp decrease in the fraction of IFN-c-producing B6/ lpr-p21tg effector and memory CD4 1 T cells ( Fig. 3A , B, top), but had no effect on the equivalent B6-p21tg T cells ( Fig. 3A, B , bottom). Definition of memory T cells by the expression of CD44 and CD62L might be inexact, and characterization of memory T cells is complex. As bona fide memory T cells are defined as small CD44 hi cells (selected by forward/side scatter) 34 , we used this definition of memory T cells, and again found that p21 overexpression greatly reduced the percentage of IFN-c-producing small B6/lpr-p21tg memory T cells ( Fig. 3C, left) , but had no effect on the equivalent B6-p21tg T cell population ( Fig. 3C, right) .
IL-17, another lupus-associated cytokine expressed by B6/lpr T cells 30, 31 , was produced by a small number of CD4 1 T cells (,3%) and was unaffected by p21 overexpression (not shown). IL-2 levels were substantially lower in B6/lpr memory T cells than in B6 controls (3.3% vs. 10.4%; Fig. S2 ), in accordance with previous reports 29 ; the p21 transgene did not affect the difference in IL-2 expression ( Fig.  S2 ). IL-4 expression was minimal (,1%) in T cells from all mice tested (not shown).
The data indicate that the p21 transgene controls not only effector/ memory T cell accumulation in B6/lpr-p21tg mice, but also regulates their intrinsic activation and IFN-c production potential.
The p21 transgene negatively regulates T cell hyperproliferation in B6/lpr-p21tg mice. An unexplained characteristic of the lpr mouse phenotype is the in vivo hyperproliferation of lymph node CD4 1 , CD8 1 and DN T cells 19, 20 cells at 2 and 4 months of age showed reduced accumulation of B6/lpr-p21tg CD44 hi CD62L hi and CD44 hi CD62L lo subsets compared to B6/lpr T cells. Values show mean from one representative experiment (n 5 4 mice; p , 10 25 for both subsets) of 3 performed. (b) Similar proportions of CD44 hi CD62L hi and CD44 hi CD62L lo CD4 1 T cells in B6 and B6-p21tg mouse lymph nodes at 2, 4 and 8 months of age. Values show mean from one representative experiment (n 5 4 mice) of 3 performed. (c) Western blot showed high p21 transgene expression in sorted naïve CD4 1 cells from B6-p21tg and B6/lpr-p21tg mice. b-actin was used as a loading control. The samples were derived from the same experiment and the two gels were run and processed simultaneously under the same experimental conditions. CD69 SS 10 0 10 1 10 2 10 3 ( Fig. 4A , B, left panels). p21 overexpression greatly inhibited lymph node CD4 1 , CD8 1 and DN T cell hyperproliferation in B6/lpr-p21tg mice (.2-fold, Fig. 4A ), but had no effect on the in vivo proliferative characteristics of B6-p21tg T cells ( Fig. 4B ). Analysis of BrdU incorporation showed much greater proliferation of effector and memory B6/lpr mouse T cells compared to B6 controls (63% vs. 23%, and 43% vs. 28%, respectively; Fig. 4C , D, left). Enhanced p21 expression had a major anti-proliferative effect on B6/ lpr-p21tg CD4 1 T cells (.68%) compared to B6/lpr effectors ( Fig. 4C , top), with less extensive but significantly reduced proliferation in the equivalent memory T cell populations (28%) (Fig. 4C , bottom). Enhanced p21 expression had no influence on effector or memory T cell subsets in B6-p21tg mice (Fig. 4D ).
Our results indicated that overexpressed p21 regulates hyperactivation, IFN-c production and hyperproliferation of B6/lpr-p21tg effector/memory T cells, with no effect on the B6-p21tg T cells. These data suggest that p21 exerts its autoimmunity-suppressive activity by controlling the increased activity and proliferation of effector T cells.
Elevated p21 expression does not modify the apoptotic defect of B6/lpr T cells. To determine whether the reduced hyperactivation and IFN-c production as well as the expansion of B6/lpr-p21 effector/memory T cells were due to attenuation of the B6/lpr T cell apoptosis defect by the p21 transgene, we used the classical AICD protocol to compare B6/lpr and B6/lpr-p21 T cell death. CD44 hi / CD62L hi CD44 hi / CD62L lo 10 0 10 1 10 2 10 3 10 0 10 1 10 2 10 3 10 0 10 1 10 2 10 3 After primary TCR stimulation with concanavalin A (ConA) and IL-2-dependent culture, B6, B6-p21tg, B6/lpr and B6/lpr-p21tg CD4 1 T cells received a second stimulation, leading to activation of the Fas/ FasL system and apoptosis. AICD was similar in B6 and B6-p21tg T cells after restimulation, as shown by a comparable apoptotic hypodiploid peak and proportion of death in cell cycle profiles ( Fig. 5A , left). In these conditions, we found a similar defect in the B6/lpr and B6/lpr-p21tg T cells, with absence of the apoptotic hypodiploid peak due to the lpr AICD defect ( Fig. 5A, right) . The results suggested that the p21 transgene had no effect on normal or defective AICD. This was confirmed by the observation that p21 transgene expression was high in B6-p21tg and B6/lpr-p21tg T cells during AICD induction. In B6/lpr-p21 T cells, the p21tg was highly expressed at the end of IL-2 treatment ( Fig. 5B , 0 h). After secondary stimulation, expression was maintained at 6, 12 and 24 h, albeit at lower levels. Endogenous p21 expression was minimal at the end of IL-2 culture: it increased in B6/lpr T cells after secondary stimulation, and more moderately in B6/lpr-p21 T cells, probably due to the p21 transgene overexpression, resulting in lower endo-genous p21 levels in B6/lpr-p21 T cells ( Fig. 5B ). Expression of transgenic and endogenous p21 was similar in B6-p21tg and B6 T cell cultures ( Fig. S3 ).
We tested apoptosis induction, using annexin-V/propidium iodide (PI) staining to confirm the cell cycle analysis results. In B6 and B6-p21tg cultures, we observed similar frequencies of apoptotic (annexin-V 1 /PI 2 ; 33.1% and 32.3%, respectively) and post-apoptotic dead T cells (annexin-V 1 /PI 1 ; 45.5% and 43.4% respectively) ( Fig. 5C ). These data indicated that p21 overexpression did not influence normal Fas/FasL-dependent AICD. In similar experiments, we carried out annexin-V/PI staining of B6/lpr and B6/lpr-p21tg T cells; apoptosis was similarly defective for both cell types, as indicated by the small percentage of apopotic T cells (,6%) in a time course study (6 to 72 h). Percentages of necrotic cells were also low (,10%) and were similar in B6/lpr and B6/lpr-p21tg T cell cultures ( Fig. 5D ).
These results indicated that the p21 transgene is expressed at different times during the AICD process, and exclude the possibility that it acts as an apoptosis-promoting factor in B6 or in apoptosis- www.nature.com/scientificreports SCIENTIFIC REPORTS | 5 : 7691 | DOI: 10.1038/srep07691 deficient B6/lpr T cells. Our findings suggest that the p21 transgene has an apoptosis-independent effect on B6/lpr-p21tg mouse effector/ memory T cells that reduces their excessive accumulation, activation and IFN-c production.
p21 overexpression reduces B6/lpr T cell activation and proliferation after repeated in vitro stimulation. We performed in vitro stimulation studies to further examine the role of the p21 transgene as an attenuator of B6/lpr-p21tg T cell activation and proliferation. In a previous study of p21 2/2 mice, we showed that p21 controls T cell expansion after secondary but not after primary stimulation 7 . Here we found reduced expansion and activation of B6/lpr-p21tg T cells after secondary stimulation, using a dual stimulation protocol with an intermediate IL-2 expansion step as described above for AICD induction. In these experiments, cultured B6/lpr and B6/lpr-p21tg T cells proliferated similarly after primary ConA stimulation, as measured by [ 3 H]thymidine uptake (Fig. 6A ). In contrast, we detected a sharp decrease (.50%) in [ 3 H]thymidine uptake in B6/ lpr-p21tg compared to B6/lpr T cells after secondary stimulation ( Fig. 6A ). Results were similar after anti-CD3 and -CD28 TCR stimulation of B6/lpr and B6/lpr-p21tg T cells (Fig. S4 ). Reduction of cell cycle progression due to p21 overexpression was further confirmed by .3-fold lower expression of the Ki-67 proliferation marker 35 in B6/lpr-p21tg than in B6/lpr T cells after secondary stimulation (Fig. 6B) . These findings were corroborated by a marked reduction (.5-fold) in the absolute number of T cells that divided in B6/lpr-p21tg vs. B6/lpr cultures at 72 h post-secondary activation, whereas there were no notable differences after primary stimulation (Fig. 6C ). The p21 transgene did not significantly affect B6-p21tg T cell [ 3 H]thymidine uptake or the number of divided T cells compared to B6 T cells after secondary or primary stimulation ( Fig. 7A, B ). To avoid Fas-dependent apoptosis of restimulated B6 and B6-p21tg T cells, we used the caspase inhibitor zVAD (benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone) in restimulation experiments. In B6/lpr and B6/lpr-p21tg secondary stimulation cultures, zVAD was used as a control to confirm that it did not influence the inhibitory effects of the p21 transgene.
We excluded the possibility that p21 overexpression in B6 T cells affected in vivo CD4 1 T cell responses, since B6 and B6-p21tg mice immunized with OVA in CFA, followed 3 weeks later by OVA challenge in IFA, showed no differences in overall memory T cell generation ( Fig. 7E ). Purified CD4 1 splenocytes from B6 and B6-p21tg mice obtained 7 days after a second OVA boost, cultured with OVA and irradiated splenocytes, showed a similar OVA response at 24 and 48 h postactivation ( Fig. 7F ). To further demonstrate that p21 does not affect normal immune T cell responses, we immunized B6 and B6-p21tg mice with vaccinia virus, an infection model that targets CD8 1 T cells. We injected B6 and B6-p21tg mice with Modified Vaccinia Ankara (MVA) virus 36 at day 0 and day 8 and immune responses were measured 10 days after the last dose. Splenocytes were stimulated with the MHC class I restricted B8R 20-27 viral peptide 37 and the response of CD8 1 spleen T cells was measured by a B6 B6-p21tg 2 nd stimulation (24h) 33 determining the proportion of IFN-c-and TNF-a-expressing CD8 1 T cells. We found similar responses for B6 and B6-p21tg CD8 1 T cells after immunization and restimulation (Fig. 7G ).
Our data show that, as in the in vivo studies, p21 limits expansion of B6/lpr-p21tg but not of B6-p21tg T cells in in vitro restimulation conditions. As p21 inhibits CDK2 and regulates proliferation, we examined CDK2 activity in B6/lpr-p21tg T cells after secondary stimulation; at 24 h post-stimulation, we found reduced CDK2 activity in B6/lpr-p21tg T cells (Fig. 6D) , which could account for their decreased expansion. Nonetheless, CDK2 activity was reduced in B6-p21tg T cells compared to B6 counterparts (Fig. 7C) , which showed similar proliferation capacity after restimulation (Fig. 7A, B) . These results raise the possibility that reduction of CDK2 activity by p21 alone is insufficient to limit the increased responses of B6/lpr T cells.
In addition to its effect on in vivo hyperproliferation, the p21 transgene lowered T cell activation and IFN-c production by B6/ lpr-p21tg CD4 1 T cells. In the dual stimulation protocol, IL-2expanded B6/lpr and B6/lpr-p21tg CD4 1 T cell populations had similar percentages (,10%) of effector cells with a CD44 hi CD62L hi phenotype, suggesting that the p21 transgene had no effect on the initial stimulation process (Fig. 6E, top) . The remaining cells had a CD44 hi CD62L lo memory cell phenotype. After secondary stimulation of B6/lpr T cells (24 h), the proportion of effectors increased from 9.6% to 35%, suggesting that a fraction of cells reverted from memory to effector phenotype as a result of activation ( Fig. 6E, left) . In B6/lpr-p21tg cultures, conversion to effector T cells was clearly lower after restimulation (22%; Fig. 6E, right) , reflecting a lower activation level. These data suggested that the p21 transgene negatively regulated B6/ lpr T cell activation after secondary stimulation. In accordance with these results, a significantly smaller fraction of restimulated B6/lpr-p21tg T cells produced IFN-c compared to B6/lpr T cells (Fig. 6F,  top) . The results coincided with our in vivo data showing a limited percentage of IFN-c-producing T cells in B6/lpr-p21tg mice. We detected no significant differences for IL-2 production in equivalent in vitro experiments (Fig. 6F, top) . In order to provide additional evidence for a role of p21 in reducing IFN-c production, we employed a model were IFN-c is directly induced. IL-12 directly drives IFN-c production, which is enhanced by IL-18 in T cells during TCR activation 38, 39 . In our case, T cells were initially stimulated with ConA, subsequently exposed to IL-2 and then triggered by IL-12, IL-18 and IL-2. Under these conditions, B6/lpr T cells showed a high proportion of IFN-c positive cells (more than 36%), while p21 transgenic expression in B6/lpr-p21tg T cells strongly inhibited IFN-c production (Fig. 6F, bottom) . These data showed that enhanced p21 expression suppresses IL-12-and IL-18-dependent IFN-c induction.
Activation anomalies corresponding to the amount of phosphorylated ERK (p-ERK) are thought to enhance autoreactivity and IFN-c production 40, 41 ; we therefore examined the regulatory effect of the p21 transgene on ERK phosphorylation of B6/lpr and B6/lpr-p21tg T cells. Western blot analysis showed p-ERK variations in B6/lpr-p21tg compared to B6/lpr T cells, in a period up to 6 h after secondary stimulation. ERK phosphorylation was lower at 0.5 and 1 h poststimulation, with higher p-ERK levels at 2 h post-activation in B6/ lpr-p21tg cultures (Fig. 6G ). An initial delay in ERK phosporylation thus led to larger amounts of p-ERK, a response pattern that might cause reduced IFN-c production by B6/lpr-p21tg T cells. p21tg expression was also confirmed after secondary activation (0-6 h; Fig. 6G ). We found no p-ERK expression differences in B6 and B6/ lpr-p21tg T cell cultures (Fig. 7D) , reinforcing our view that p21 overexpression affects lpr but not normal T cells.
The results indicate that, as for B6/lpr-p21tg T cells in vivo, p21 transgene expression regulates overexpansion, overactivation and increased IFN-c production by B6/lpr T cells in vitro.
Reduction of hyperproliferating effector/memory T cells ameliorates autoimmune disease manifestations in B6/lpr mice. B6/lpr mice show mild autoimmunity compared to the lethal lupus-like autoimmune glomerulonephritis in MRL/lpr mice; B6/lpr mice nevertheless develop a large effector/memory T cell population as well as anti-DNA autoantibodies and slight lymphadenopathy 18 . T cell-directed p21 overexpression in B6/lpr mice reduced not only the effector/memory T cell compartment, but also activation of IFN-c production by these cells. As IFN-c is indispensable for anti-DNA autoantibody production 19 , we predicted a decrease in these autoantibodies in B6/lpr-p21tg mice; indeed, we observed a sharp drop in anti-DNA antibodies in B6/lpr-p21tg mouse serum compared to B6/lpr controls (Fig. 8A) . Although the effect of the p21 transgene leads to reduced T cell activation and associated disease manifestations, alternatively, increased p21 expression may affect disease development in a paracrine manner. As macrophage activation is critical for lpr disease development 42 , we examined whether these cells could be affected by the p21 transgene in such manner. Peritoneal B6/lpr macrophages were exposed to culture supernatants from repeatedly stimulated B6/lpr or B6/lpr-p21tg T cells. The concentration of IFN-c in T cell culture supernatants was strongly reduced in the presence of the p21 transgene (Fig. S7) . While the supernatants from B6/lpr T cells highly activated macrophages, as seen by high STAT1 phosphorylation and iNOS induction, equivalent supernatants from B6/lpr-p21tg showed lower STAT1 phosphorylation and abolished iNOS induction (Fig. S7 ). These data also suggest that iNOS is induced only by high IFN-c levels, a result that was supported by exposing macrophages to different IFNc concentrations. Overall the results highlight the potential of p21 overexpression to control essential disease components in a paracrine fashion.
B6/lpr mice develop lymphadenopathy and splenomegaly, caused mainly by DN T cell accumulation. Expansion of this cell subset is evident at two months of age and increases with time. p21 overexpression led to a clear reduction in the DN T cell population in B6/lpr-p21tg mice (Fig. 8B) . Consistent with this decrease, lymphadenopathy was notably reduced in these mice compared to B6/lpr controls, with greatly diminished lymph node size and weight (Fig. 8C ). We detected no endogenous p21 expression in DN T cells (Fig. 8D ). This lack of p21 probably explains the hyperproliferation of these cells, whereas transgenic p21 expression ( Fig. 8D) reduced their hyperproliferation and hyperactivation. In agreement with the inhibition of DN cell hyperactivation, we found a profound reduction in IFN-c-and IL-17-producing DN T cells in B6/lpr-p21tg mice (Fig. 8E) .
As DN T cells arise from CD8 1 T cells 43 we examined the in vitro characteristics of B6/lpr-p21tg and B6/lpr CD8 1 T cells purified from the spleens of 2-months-old mice. The data showed that after secondary stimulation B6/lpr-p21tg CD8 1 T cells proliferate at much lower levels compared to B6/lpr CD8 1 T cells, as tested by cell cycle and BrdU analyses (Fig. S8) . In contrast to DN T cells which hyperproliferated in vivo, the DN cells, which were generated by CD8 1 T cells in in vitro cultures 44 , accumulated as non-proliferating cells, as shown by cell cycle and BrdU analyses. The percentage of accumulated DN T cells after secondary stimulation was similar for both B6/ lpr and B6/lpr-p21tg CD8 1 T cell cultures (approximately 10%) ( Fig.  S8) , indicating that p21 affects DN T cell expansion only in vivo.
These data show that T cell-directed expression of the p21 transgene had a dual effect in B6/lpr mice; first, it lessened autoimmune manifestations, due to the transgene effect on IFN-c production, and second, it limited DN T cell-induced lymphadenopathy by reducing DN T cell hyperactivation and hyperproliferation. p21 overexpression reduces lupus-like autoimmunity and increases MRL/lpr mouse survival. As p21 overexpression in B6/lpr-p21tg T cells limited autoimmune symptoms and lymphadenopathy in B6/lpr mice, we tested its potential to inhibit the severe, death-inducing autoimmunity in MRL/lpr mice. T cell-www.nature.com/scientificreports SCIENTIFIC REPORTS | 5 : 7691 | DOI: 10.1038/srep07691 directed p21 overexpression reduced the percentage of lymph node DN T cells as well as lymphadenopathy development (Fig. S5) in MRL/lpr-p21tg compared to MRL/lpr mice.
MRL/lpr-p21tg mice showed sharply reduced (.4-fold) anti-DNA antibody levels that decreased nearly to values for MRL-Mp controls, which develop mild autoimmunity later in life (Fig. 9A ). As MRL/lpr mice have much higher anti-DNA antibody levels than B6/ lpr mice, p21 overexpression appeared to control the predisposition to severe autoimmunity. Compared to MRL/lpr mice, MRL/lpr-p21tg mice showed clear improvement in critical aspects of lupuslike kidney disease such as lower immune complex deposition, decreased inflammatory infiltration of CD4 1 T cells and F4/80 1 macrophages (Fig. 9B) , and reduced glomerulonephritis (Fig. 9C) . These data were corroborated by proteinuria analysis showing significantly reduced proteinuria for MRL/lpr-p21tg compared to MRL/lpr mice (1.51 vs 4.01, n 5 10 mice per group; p , 10 23 ). This p21 transgene effect on MRL/lpr disease manifestations resulted in extended survival of MRL/lpr-p21tg mice (Fig. 9D) .
These findings indicate that p21 is a potent suppressor of autoimmunity, as it can restrain autoimmune symptoms and death associated with severe lupus-like disease in the MRL/lpr mouse model.
Discussion
Deficiency in p21 when combined with autoimmunity-prone backgrounds leads to severe lupus-like disease and death, suggesting that p21 moderates autoimmunity progression 5,6 . On the other hand, lack of p21 in normal background mice results only in mild autoreactivity 7 , questioning a possible effect of p21 in autoimmunity treatment. The aim of the present study was to explore a p21 therapeutic effect by increasing its expression levels in T cells of B6/lpr and MRL/lpr mice. We showed that enhanced p21 levels suppressed autoreactivity and DN T cell lymphadenopathy in B6/lpr-p21tg mice and effectively targeted severe autoimmune disease and death in MRL/lpr-p21tg mice and led to three principal conclusions. First, we provided direct evidence for a role of p21 in regulating autoimmunity through a p21 function on effector/memory lpr T cells that limits their accumulation, activity and IFN-c production. Second, we established that preactivated but not naïve lpr T cells require elevated p21 expression to control activation. Finally, since normal background B6-p21tg T cells remained unaffected by increased p21, our work imparts an experimental model that specifically targets autoimmune, but not normal immune responses.
In B6/lpr mice, activated T cells increase with age as effector/ memory or DN T cells. Fas deficiency leads to defective AICD in in vitro conditions but deficient T cell apoptosis has not yet been shown in vivo in the absence of Fas 18 . Instead, all lpr T cell subsets exhibit a hyperactivation state and hyperproliferate [45] [46] [47] , suggesting that alternative Fas functions may control lpr T cell proliferation 24 . T cell-specific p21 overexpression severely reduces effector/memory and lpr DN T cell expansion. We did not detect a role for overexpressed p21 in AICD induction, as B6/lpr and B6/lpr-p21tg T cells showed similarly defective apoptosis after secondary stimulation, and AICD was similar for B6 and B6-p21tg T cells. Therefore we ruled out the possibility that transgenic p21 reduced lpr DN and effector/memory T cells by promoting their apoptosis. Together with data from a previous study that showed similar apoptosis for restimulated B6 and B6 p21 2/2 T cells 7 , these results demonstrate that p21 is not involved in typical Fas/FasL-dependent AICD events. Furthermore, our data suggest that the in vivo expansion of DN cells is driven by an uncontrolled cell cycle progression, which is dissociated from the absence of apoptosis.
The control of the effector/memory T cell population in B6/lpr-p21tg mice was the result of a reduced T cell activation accompanied by a sharp limitation of the proportion of T cells that secrete IFN-c. These data suggest that overexpressed p21 does not act as a mere cell cycle inhibitor and may possess other properties in controlling T cell responses. Other studies have shown that p21 interferes with the NF-kB activation pathway in macrophages 11 or controls the anergic state of chemically-induced T cell anergy 48 , independently of its cell cycle inhibitor function. Exogenous p21 did not affect the effector/memory T cell population of normal background B6-p21tg mice and did not influence their activation and IFN-c production. These data indicate that endogenous p21 is sufficient to control normal T cells and that increased p21 levels do not influence the responses of B6-p21tg T cells. In agreement with this view, classical immunization with OVA or with vaccinia virus showed similar responses of B6 and B6-p21tg T cells. It is, therefore, here established that autoimmune lpr T cells require higher p21 levels in order to control their activation, as compared to normal T cells that remain unaffected by exogenous p21.
In vitro studies validated the above results, showing that after secondary stimulation B6/lpr-p21tg T cells acquired a less activated phenotype and produced less IFN-c than those from B6/lpr mice. Importantly, direct induction of IFN-c by IL-12 and IL-18, following primary stimulation and IL-2 treatment, was significantly inhibited by the p21 transgene. These findings indicate that overexpressed p21 may interfere with the IFN-c induction pathway. The decreased proliferation of B6/lpr-p21tg T cells was accompanied by a reduction of CDK2 activation, suggesting that exogenous p21 may target proliferation through its effect on CDK2. However, B6-p21tg T cells also showed diminished CDK2 activity but proliferated similarly to B6 T cells. Theses results support the view that differences in CDK2 activation do not always translate into proliferation differences, as CDK2 is a dispensable target for cell cycle inhibition 49, 50 . Therefore, in addition to CDK2 inhibition overexpressed p21 may also modulate the expansion of lpr T cells by altering their degree of activation. Accordingly, p21 affected ERK phosphorylation in B6/lpr-p21tg but not in B6-p21tg T cells. Other studies show association between p-ERK levels and IFN-c production showing that ERK reduction leads to decreased or increased IFN-c production by T cells 40, 41 . We suggest that p21-dependent alteration of ERK phosphorylation www.nature.com/scientificreports may reduce IFN-c production in restimulated B6/lpr-p21tg T cells, a point that will be addressed in depth in a later study.
Exogenous p21 had no effect on activation and IFN-c production capacity of restimulated B6-p21tg T cells, corroborating the in vivo results. These data reaffirm the differential requirements of autoimmune and normal T cells in controlling their activation state, as p21 was similarly expressed in both cell types. Primary B6-p21tg and B6/lpr-p21tg T cell responses were not affected, showing that p21 overexpression is specifically targeting repeatedly stimulated lpr T cells. Thus, p21 overexpression does not inhibit autoimmunity through a general suppression of T cell responses, a result that is further supported by data showing that exogenous p21 does not affect T cell development in the thymus. p21 overexpression markedly inhibited lymphadenopathy development in both B6/lpr-p21tg and MRL/lpr-p21tg mice. As DN T cell hyperactivation is directly linked to their hyperproliferation and accumulation 45 , p21 could regulate their expansion. Indeed, exogenous p21 greatly reduced IFN-c and IL-17 overexpression by these cells, which is linked to hyperresponsiveness 51 , suggesting that p21 regulation of T cell activity could be used in therapeutic design for ALPS patients.
Overexpressed p21 compromised the capacity of effector/memory B6/lpr-p21tg T cells to produce IFN-c, which is necessary for anti-DNA autoantibody and lupus-like autoimmunity development 19, 42 . These results suggest that overexpressed p21 reduces T cell activation and IFN-c secretion, which lead to downmodulation of anti-DNA antibody production. In addition, in vitro data suggest a possible paracrine effect of p21 transgene in disease development, since the differential IFN-c secretion by B6/lpr and B6/lpr-p21tg T cells greatly affected macrophage activation and inflammatory potential. MRL/ lpr mice develop severe autoimmune disease and suffer early mortality due to the concurrence of the lpr mutation and the MRL autoimmunity-promoting background. T cell-directed p21 overexpression strongly limited MRL/lpr-p21tg mice mortality by greatly reducing anti-DNA autoantibody production and kidney inflammatory infiltrates. Furthermore, it diminished the DN T cell numbers, as well as their potential to produce inflammatory cytokines, which is related to pathogenicity 51 . These data support a strong therapeutic role for p21 in increased autoreactive T cell responsiveness and in maintaining autoimmunity at bay.
Elevated IFN-c levels are associated with SLE 52, 53 , and clinical trials are currently testing the humanized anti-IFN-c monoclonal antibody AMG 811 for lupus treatment (Amgen). In this context, our results suggesting that p21 inhibits autoimmunity by modulating IFN-c could have therapeutic interest. General alterations in the activation machinery and reduced p21 levels in lupus patient T cells 54, 55 corroborate the therapeutic potential of our findings. The data also suggest that autoimmune memory T cell hyperresponsiveness can be reduced without affecting normal T cell responses, which would evidently constitute an ideal treatment for lupus and other autoimmune diseases. While therapeutic use of p21 overexpression might not appear to be an immediate option in humans, analysis of the mechanism by which high p21 levels reduce memory T cell expansion could provide a discovery platform for p21-associated factors suitable for clinical intervention. Finally, the selective effect of p21 on autoimmune but not normal T cells supports the idea of developing therapeutic approaches that do not affect normal immunity but robustly target autoimmune pathology.
Methods
Mice. Control C57BL/6 mice were obtained from Harlan Interfauna Ibérica; C57BL/ 6-lpr (B6.MRL-Tnfrsf6lpr) were from Jackson Laboratories. In C57BL/6-lpr-p21tg mice, generated from C57BL/6-lpr and C57BL/6-p21tg mice, transgene expression was restricted to T cells by the proximal Lck promoter 26 . Mice were kept in SPF conditions. All mouse experiments were performed in accordance with European Union and national regulations, and were approved by the CNB Bioethics Committee.
Flow cytometry. Stained cells were analyzed on an LSR cytometer (Becton Dickinson). To determine memory phenotype, CD4 1 T cells were stained with anti-CD8-PEcy7 (Biolegend), -CD4-PE, -CD44-FITC and -CD62L-APC (Beckman Coulter) antibodies. For double negative population analysis, cells were stained with anti-CD4-FITC (PharMingen), -CD8-PEcy7, -B220-APC (Beckman Coulter) and -TCR-PE (PharMingen) antibodies.
BrdU was detected with an anti-BrdU-FITC antibody (Becton Dickinson) combined with -CD4-Pecy7 (eBioscience), -CD8-SPRD (Beckman Coulter), -CD44-biot (PharMingen), Av-SPRD (Beckman Coulter), -CD62L-PE (Southern) and -TCR-PE (PharMingen) antibodies. To distinguish live from dead cells, we preincubated cells with the LIVE/DEAD stain kit (Invitrogen) according to manufacturer's instructions. Only live cells were considered for analyses.
Cell culture. Mouse CD4 1 spleen T cells were purified by Negative Isolation Kit (Dynal Biotech); .85% pure CD4 1 T cells were obtained. In some experiments, naïve CD4 1 /CD44 low /CD62L hi cells were obtained by a combination of negative isolation and sorting on an Epics Altra sorter (Beckman Coulter) after staining with anti-CD44 and -CD62L antibodies. Purified naïve T cells (10 6 /ml) were stimulated in vitro with concanavalin A (ConA; 3 mg/ml, Sigma) in medium containing 20 ng/ml human recombinant interleukin-2 (rIL-2, PeproTech) or in medium conditioned with anti-CD28 (PharMingen; 1 mg/ml) in wells coated with anti-CD3 antibody (PharMingen; 1 mg/ml in 100 ml/well PBS). After 3 days, cells were washed and cultured in medium with 20 ng/ml IL-2 (24 h), followed by restimulation with IL-2 in combination with either ConA or anti-CD3/CD28 or IL-12 (10 ng/ml) plus IL-18 (10 ng/ml). In some cultures, the caspase (zVAD; 50 mM/ml, Bachem) was added.
Mouse CD8 1 T cells were isolated from spleen by a negative isolation kit (Dynabeads Untouched Mouse CD8 cells, Invitrogen) and stimulated in vitro with ConA (3 mg/ml, Sigma) in complete RPMI, containing 20 ng/ml human recombinant interleukin-2 (rIL-2, PeproTech). After 3 days, cells were washed and cultured in medium with 20 ng/ml rIL-2 (24 h), followed by ConA restimulation for 24 h. During the last 3 hours, BrdU was added at a final concentration of 6.5 mg/ml and the cells were processed for flow cytometry and stained with the combination of anti-TCRb, anti-CD8, anti-CD4 and anti-BrdU antibodies. Alternatively, cells were stained with anti-CD8-PE and 2 mg/ml 49,6-diamidino-2-phenylindole (DAPI) for cell cycle analysis.
For macrophage cultures, peritonal exudate cells (PEC) were harvested from B6/lpr mice that were injected i.p. with 1 ml of 3% thioglycollate medium (Difco) 4 days before isolation. PEC were cultured for 2 h in RPMI 1640 without FBS and nonadherent cells were removed by washing with PBS and adherent macrophages were cultured overnight in complete RPMI 1640 with 10% FBS. Cells were incubated for 20 h in the presence of 152 diluted cell-free culture supernatants from B6/lpr or B6/ lpr-p21tg T cells (collected 24 h after second ConA stimulation). Control cells were cultured in medium alone or stimulated for 20 h with IFN-c (100 or 50 U/ml, Sigma).
OVA immunization and in vitro stimulation. B6 and B6-p21tg mice were immunized with 100 mg OVA (Sigma-Aldrich) and CFA as previously described 7 . After 3 weeks, mice received a second OVA boost in IFA; mice were sacrificed one week later and lymph node cells were stained to quantify memory CD4 1 T cells. In addition, CD4 1 cells were purified from spleens of B6 and B6-p21tg mice one week after the second OVA boost using Dynabeads as above. Cells were OVA-stimulated in vitro (100 mg/ml; 10 5 cells/ml; 24 h) in RPMI 1640 containing 10% FCS with irradiated splenocytes (0.5 3 10 6 /ml). Proliferation was measured using [ 3 H]thymidine as above.
Vaccinia virus infection and in vitro stimulation. B6 and B6-p21tg mice were immunized by i.p. injections at Day 0 and Day 8 with 1 3 10 7 PFU of Modified Vaccinia Ankara (MVA) virus 36 . At Day 18, mice were sacrificed and erythrocytedepleted spleen cells were resuspended in RPMI 1640 with 10% FCS and 1 mg/ml GolgiPlug (BD) and stimulated (6 h, 37uC, 5% CO 2 ) with B8R 20-27 peptide of vaccinia virus (sequence: TSYKFESV, CNB, Proteomics Facility) at a final concentration of 10 mg/ml. Intracellular cytokine staining. For intracellular cytokine staining, lymph node T cells or cells after primary ConA activation and IL-2 expansion were stimulated (1 h, 37uC) in medium with phorbol 12-myristate 13-acetate (PMA; 50 ng/ml) and ionomycin (2 mg/ml). Brefeldin A (GolgiPlug, 20 ml/ml; BD PharMingen) was added and cells incubated (3 h, 37uC). After surface marker staining with appropriate combinations of labeled anti-CD4, -CD8, -Thy1, -CD44, and -CD62L, cells were washed with PBS, fixed and permeabilized with Cytofix/Cytoperm (100 ml, 20 min, 4uC), washed once with Perm/Wash buffer and blocked with 150 ml Perm/Wash buffer 1 1% BSA (30 min, room temperature (RT)). Anti-IL-17-PE, -IL-2-PE and -IFNc-PE antibodies were added (all 1/100, PharMingen); permeabilized cells were incubated (20 min, 4uC) and washed twice in Perm/Wash before FACS analysis.
For the vaccinia infection experiment, splenocytes were stained for surface markers with anti-CD3-PE-CF594, -CD4-APC-Cy7, -CD8-V500 (all from BD), fixed, permeabilized (Cytofix/Cytoperm kit; BD), and stained intracellularly with anti-IFNc-PE, and -TNFa-PE-Cy7 (from BD). Dead cells were excluded using the violet LIVE/ DEAD stain kit (Invitrogen).
In vivo BrdU administration. Mice were given BrdU (0.8 mg/ml; Sigma-Aldrich) in drinking water, which was prepared fresh every 2 days for a 9-day period, and BrdU incorporation was determined in lymph node T cells. Cells were stained with www.nature.com/scientificreports
